Practice Areas & Industries: Greenberg Traurig, LLP


Mergers & Acquisitions Return to Practice Areas & Industries

Group Profile Lawyers in this Group Offices Locations for this Group

Practice/Industry Group Overview

 Public and private companies turn to Greenberg Traurig for their M&A transactions. We advise both middle market transactions and billion dollar deals. Our practice has a global reputation for the services our team provides to companies and entrepreneurs throughout the Americas, Europe, Asia and Africa. We have particularly strong experience with cross-border transactions across a wide range of industries and representing leading investment banking and financial advisory firms.

Greenberg Traurig has been acknowledged by numerous rankings and independent surveys, recognizing the depth and experience of our practice:

  • Named one of America’s Best Corporate Law Firms by annual survey of directors and general counsel of publicly traded companies. (Corporate Board Member’s 6th Annual Legal Recognition Survey 2013)
  • Ranked #1 for announced M&A transactions in Florida, based on value (mergermarket 2012 Roundup)
  • Ranked #1 for announced M&A transactions in Poland, based on value (mergermarket H1 2013)
  • Law Firm of the Year in Poland-M&A (Dealmakers M&A Awards 2012)
  • Named M&A Law Firm of the Year for North America (Americas Atlas Awards for Mid-Market Deals, 2011)
  • Ranked #9 among all law firms advising on private technology M&A acquisitions, based on volume (PrivCo 2012 Annual Private Tech Company M&A Rankings)
  • Ranked #4 among all law firms in representing investment banks in M&A transactions with 17 announced transactions (Corporate Control Alert 2012 Banker Representations)
  • Ranked #2 for Corporate/M&A Nationwide: Highly Regarded (Chambers & Partners USA, 2013 Directory)
  • Named as Winner for: M&A Deal of the Year (Over $200mm to $500mm), Corporate/Strategic Acquisition of the Year (Over $250mm), Consumer Services, Consumer and Retail Products Deal of the Year (Over $200mm)  (ACG New York Champion’s Awards 2013)
  • Ranked #2 Investor Law Firm and #3 Issuer Law Firm, ranked by number of Pipes transactions advised in 2011(PrivateRaise A service of DealFlow Media - 2011 PIPE Market League Tables)
  • Named “Winner” of three awards and “Finalist” in three additional categories at the 11th Annual M&A Advisor Awards:
    • M&A Deal of the Year (over $2.5 billion)
    • Cross-Border Deal of the Year (over $500 million)
    • Consumer and Retail Products Deal of the Year (over $500 million) (The M&A Advisor 2012)
  • Named a “National Tier 1” Law Firm for Mergers & Acquisitions, Securities/Capital Markets Law, Banking and Finance Law, and Corporate Law (U.S. News and Best Lawyers, Best Law Firms Rankings 2011)
  • Energy Deal of the Year awarded for our representation of APR Energy in its $855 million sale to Horizon Acquisition Company Plc. (Americas Atlas Awards for Mid-Market Deals 2011)

Mergers & Acquisitions

  • Our Corporate & Securities team of approximately 350 attorneys is routinely chosen to handle critical M&A matters for companies and organizations
  • We help our clients structure, negotiate and consummate complex international and domestic sale of control transactions, strategic business combinations, and complex recapitalization transactions primarily for large and middle cap companies, and for unlisted, controlled and privately owned-businesses
  • Our M&A practice includes:
    • Negotiated and contested mergers and acquisitions
    • Sales and purchases of assets
    • Subsidiaries and divisions
    • Election contests and dissident shareholder proposals
    • Tender and exchange offers
    • Going-private transactions
    • MBOs
    • Spin-offs
    • Auctions
    • Anti-takeover defense initiatives
    • Special committee, fairness opinion and corporate governance engagements
    • Transactional and M&A advisory matters 
  • We represent the following entities in all types of M&A transactions:
    • Buyers
    • Sellers
    • Investors
    • Shareholders
    • Boards of directors
    • Special committees
    • Financial advisors
    • Private equity and hedge funds
    • Investment banks
    • Broker-dealers
    • Commercial lenders
  • We serve clients from many industries, including:
    • Aviation
    • Banking
    • Energy
    • Entertainment
    • Financial services
    • Health care
    • Life sciences
    • Manufacturing
    • Medical devices
    • Pharmaceutical
    • Real estate
    • Technology
    • Telecommunication
    • Transportation

Past Seminar Materials
  Tulane University Law School - 25th Tulane Corporate Law Institute, March 21, 2013
Articles Authored by Lawyers at this office:

Assistant Attorney General Baer Reports on Recent Developments in DOJ Remedies and Enforcement Policies
Gregory J. Casas, November 21, 2013
On September 25th, Bill Baer, Asst. Attorney General in charge of the Antitrust Division of the Department of Justice (DOJ), spoke at the Georgetown Law 7th Annual Global Antitrust Enforcement Symposium on recent developments in the DOJ's enforcement policy. The speech provided practitioners and...

EU Merger Control and Minority Shareholdings: Time to Plug the Enforcement Gap?
Simon Harms,Irving Scher, November 21, 2013
First created in 1989, the European Union (EU) merger control regime has now been around for the better part of a quarter of a century and is a well-established fact of life for businesses involved in large-scale M&A transactions. During that time, the European Commission (the Commission) has...

Final Rules Adopted, Making More Pharmaceutical Patent Transfers Subject to the HSR Act: Increased Review Raises Importance of Valuation
Mary K. Marks, November 21, 2013
On November 6, 2013, the Federal Trade Commission (FTC) in consultation with the U.S. Department of Justice issued final amendments to the premerger notification rules regarding when a transfer of rights to a pharmaceutical patent is reportable under the Hart-Scott-Rodino (HSR) Act. The commission...

New HSR Rules Will Require More Filings for Pharmaceutical Patent Transfers: Increased Review Raises Importance of Valuation
Mary K. Marks, November 11, 2013
Amendments to the Rules under the Hart-Scott-Rodino (HSR) Act have been adopted that will require compliance with the Act’s reporting and waiting period requirements for certain acquisitions of exclusive pharmaceutical patent licenses that historically have not been reportable because the...